Skip to main content
Fig. 1 | BMC Psychiatry

Fig. 1

From: The Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations, Outcomes (REACH-OUT) study: real-world clinical practice in schizophrenia

Fig. 1

Study design. APT, antipsychotic; ASI-Lite, Addiction Severity Index Lite; BL, baseline (enrollment); DAI-10, Drug Attitude Inventory 10-item scale; Dx, diagnosis; LAI, long-acting injectable (includes paliperidone palmitate long-acting injectable and risperidone long-acting injectable); MSQ, Medication Satisfaction Questionnaire; PP LAI, paliperidone palmitate long-acting injectable; RLAI, risperidone long-acting injectable; Tx, treatment. *Entered within 8 weeks of start or switch to RLAI or other antipsychotic, after >24 weeks of continuous RLAI treatment, or any time after initiation of PP LAI. Asked of cohort that included participants newly initiated on an antipsychotic at baseline

Back to article page